SCHEMBL349060

SCHEMBL349060

O=Cc1ccc(OCC(=O)O)cc1

nearest known ligand 0.62

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.61
ALDH1A1 P00352 7/20 0.56
SMN1; SMN2 Q16637 1/20 0.55
FFAR1 O14842 1/20 0.55
GPR35 Q9HC97 1/20 0.54
PTPN7 P35236 2/20 0.53
KMT2A Q03164 2/20 0.53
MEN1 O00255 1/20 0.53
MAPT P10636 1/20 0.53
PTPN12 Q05209 1/20 0.53
TSHR P16473 1/20 0.50
NR4A1 P22736 1/20 0.50
APEX1 P27695 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Succinimide SCHEMBL29278529 0.86 GPR35 (0.57) ALOX15ALDH1A1SMN1; SMN2FFAR1GPR35
4-Aminophenol SCHEMBL10751612 0.86 ALDH5A1 (0.47) ALOX15ALDH1A1SMN1; SMN2GPR35
SCHEMBL20024689 0.86 ALOX15 (0.63) ALOX15ALDH1A1SMN1; SMN2FFAR1GPR35
SCHEMBL339492 0.85 ALOX15 (0.81) ALOX15ALDH1A1SMN1; SMN2FFAR1PTPN7
SCHEMBL6831669 0.84 ALDH1A1 (0.52) ALOX15ALDH1A1SMN1; SMN2GPR35MAPT
SCHEMBL4886687 0.84 PTPN7 (0.65) ALOX15ALDH1A1SMN1; SMN2FFAR1GPR35
SCHEMBL4346327 0.82 ALOX15 (0.59) ALOX15ALDH1A1SMN1; SMN2FFAR1GPR35
SCHEMBL9217749 0.82 ALOX15 (0.59) ALOX15ALDH1A1SMN1; SMN2FFAR1GPR35
SCHEMBL20391698 0.82 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2GPR35KMT2AMAPT
SCHEMBL246234 0.82 ALDH1A1 (0.54) ALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 583 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119529014-A Tripterine-platinum (IV) complex with antitumor activity and preparation method and application thereof 河北大学 2025-02-28 CN claimed
CN-102621326-B Method for detecting furaltadone metabolite content in food UNIV SOOCHOW 2014-08-06 CN claimed
CN-102621326-A Method for detecting furaltadone metabolite content in food UNIV SOOCHOW 2012-08-01 CN claimed
US-8158809-B2 Podophyllotoxin derivatives SUTTER WEST BAY HOSPITALS (US) 2012-04-17 US claimed
US-20090298870-A1 PODOPHYLLOTOXIN DERIVATIVES Sutter West Bay Hospitals, dba California Pacific Medical Center and Catholic Healthcare West 2009-12-03 US claimed
US-20070130702-A1 Dyeing process using a specific compound containing active methylene and a compound chosen from a specific aldehyde, a specific ketone, a quinone and a diiminoisoindoline or 3-aminoisoindolone derivative L'OREAL S.A. 2007-06-14 US claimed
US-20070110844-A1 REDUCED SWEETNESS CONFECTIONARY COMPOSITIONS AND COATED/FILLED FOOD PRODUCTS GENERAL MILLS, INC. 2007-05-17 US claimed
US-7204857-B1 Dyeing method using a specific active methylene compound and a compound selected among a specific aldehyde, a specific ketone, a quinone and a di-imino-isoindoline or 3-amino-isoindolone derivative L'OREAL S.A. (FR) 2007-04-17 US claimed
US-7166696-B2 Solid phase synthesis supports and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-01-23 US claimed
US-20040265899-A1 Solid phase synthesis supports and methods 3M INNOVATIVE PROPERTIES COMPANY 2004-12-30 US claimed
US-20040028702-A1 Muramic acid derivative compounds MALETIC MILANA M (US) 2004-02-12 US claimed
EP-1373167-A2 SOLID PHASE SYNTHESIS SUPPORTS AND METHODS 3M Innovative Properties Company (US) 2004-01-02 EP claimed
US-6635090-B1 Dyeing method using a specific cationic derivative and a compound selected among a specific aldehyde, a specific ketone, a quinone and a di-imino-isoindoline or 3-amino-isoindolone derivative L'OREAL, S.A. (FR) 2003-10-21 US claimed
US-20020173051-A1 Solid phase synthesis supports and methods 3M INNOVATIVE PROPERTIES COMPANY 2002-11-21 US claimed
WO-2002081078-A2 SOLID PHASE SYNTHESIS SUPPORTS AND METHODS 3M INNOVATIVE PROPERTIES COMPANY (US) 2002-10-17 WO claimed
US-6458168-B1 Hair dyeing method using an aliphatic cationic amine and compound chosen from an aldehyde, a ketone, a quinone, a di-imino-isoindoline, and a 3-aminoisoindolone derivative L'OREAL S.A. (FR) 2002-10-01 US claimed
US-6451067-B1 HAIR DYE MIXTURE L'OREAL S.A. (FR) 2002-09-17 US claimed
EP-0159864-B1 METHOD OF MODIFYING TASTE TATE & LYLE PUBLIC LIMITED COMPANY (GB) 1989-07-19 EP claimed
EP-0159864-A2 Method of modifying taste TATE & LYLE PUBLIC LIMITED COMPANY (GB) 1985-10-30 EP claimed
US-4017313-A Photosensitive composition containing a leuco dye, a photosensitizer, an aromatic aldehyde and a secondary or tertiary amine and the use thereof in a direct-print process E. I. DU PONT DE NEMOURS AND COMPANY (US) 1977-04-12 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070130702-A1 Dyeing process using a specific compound containing active methylene and a compound chosen from a specific aldehyde, a specific ketone, a quinone and a diiminoisoindoline or 3-aminoisoindolone derivative KRT18, NDUFB5, NDUFB7 ALOX15 1273/4885ALDH1A1 83/4885SMN1; SMN2 3654/4885
US-20020173051-A1 Solid phase synthesis supports and methods FES, LSS, CCNK ALOX15 2003/4885ALDH1A1 2966/4885SMN1; SMN2 1357/4885
US-20040028702-A1 Muramic acid derivative compounds APEH, PEPD, OGT ALOX15 2986/4885ALDH1A1 3455/4885SMN1; SMN2 4174/4885
US-20040265899-A1 Solid phase synthesis supports and methods FES, LSS, CCNK ALOX15 2003/4885ALDH1A1 2966/4885SMN1; SMN2 1357/4885
US-20090298870-A1 PODOPHYLLOTOXIN DERIVATIVES APEH, DAGLA, DPY30 ALOX15 377/4885ALDH1A1 285/4885SMN1; SMN2 4445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.